在EMPEROR-Preserved试验中，终点定义对恩格列净治疗主要肾脏结局的影响。 - Suppr

Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial.

作者信息

Packer Milton, Zannad Faiez, Butler Javed, Filippatos Gerasimos, Ferreira Joao Pedro, Pocock Stuart J, Brueckmann Martina, Zeller Cordula, Hauske Sibylle, Anker Stefan D

机构信息

Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.

Imperial College, London, UK.

出版信息

Eur J Heart Fail. 2021 Oct;23(10):1798-1799. doi: 10.1002/ejhf.2334. Epub 2021 Aug 30.

DOI:10.1002/ejhf.2334

PMID:34459076

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9291539/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d1d/9291539/413e1c82dc5b/EJHF-23-1798-g001.jpg

相似文献

Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial.

Eur J Heart Fail. 2021 Oct;23(10):1798-1799. doi: 10.1002/ejhf.2334. Epub 2021 Aug 30.

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.

Circulation. 2021 Jan 26;143(4):337-349. doi: 10.1161/CIRCULATIONAHA.120.051824. Epub 2020 Nov 11.

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.

Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30.

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.

Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.

Eur J Heart Fail. 2020 Dec;22(12):2383-2392. doi: 10.1002/ejhf.2064.

Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions.

Eur J Heart Fail. 2022 Aug;24(8):1400-1405. doi: 10.1002/ejhf.2558. Epub 2022 Jun 5.

Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled.

Circulation. 2023 Jan 3;147(1):101-104. doi: 10.1161/CIRCULATIONAHA.122.062644. Epub 2022 Nov 7.

Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved.

Nat Rev Cardiol. 2021 Nov;18(11):737. doi: 10.1038/s41569-021-00627-z.

Empagliflozin and Major Renal Outcomes in Heart Failure.

N Engl J Med. 2021 Oct 14;385(16):1531-1533. doi: 10.1056/NEJMc2112411. Epub 2021 Aug 27.

Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.

Eur J Heart Fail. 2019 Oct;21(10):1279-1287. doi: 10.1002/ejhf.1596. Epub 2019 Sep 16.

引用本文的文献

Pathophysiological Link and Treatment Implication of Heart Failure and Preserved Ejection Fraction in Patients with Chronic Kidney Disease.

Biomedicines. 2024 Apr 30;12(5):981. doi: 10.3390/biomedicines12050981.

A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials.

Nat Med. 2024 May;30(5):1432-1439. doi: 10.1038/s41591-024-02941-8. Epub 2024 May 6.

The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment.

Card Fail Rev. 2024 Apr 3;10:e05. doi: 10.15420/cfr.2023.13. eCollection 2024.

Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side.

J Clin Med. 2024 Feb 7;13(4):956. doi: 10.3390/jcm13040956.

Sodium-Glucose Cotransporter Protein 2 Inhibitors: Novel Application for the Treatment of Obesity-Associated Hypertension.

Diabetes Metab Syndr Obes. 2024 Jan 26;17:407-415. doi: 10.2147/DMSO.S446904. eCollection 2024.

Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.

Cardiovasc Diabetol. 2023 Nov 16;22(1):316. doi: 10.1186/s12933-023-02023-y.

Advance in the pharmacological and comorbidities management of heart failure with preserved ejection fraction: evidence from clinical trials.

Heart Fail Rev. 2024 Mar;29(2):305-320. doi: 10.1007/s10741-023-10338-x. Epub 2023 Aug 10.

SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review.

Endocr Connect. 2023 Jul 31;12(8):e230005. doi: 10.1530/EC-23-0005.

Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes.

Int J Mol Sci. 2023 Feb 23;24(5):4405. doi: 10.3390/ijms24054405.

Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis.

Front Cardiovasc Med. 2023 Feb 7;10:1046194. doi: 10.3389/fcvm.2023.1046194. eCollection 2023.

本文引用的文献

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.

Circulation. 2021 Oct 19;144(16):1284-1294. doi: 10.1161/CIRCULATIONAHA.121.056824. Epub 2021 Aug 29.

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.

Empagliflozin and Major Renal Outcomes in Heart Failure.

N Engl J Med. 2021 Oct 14;385(16):1531-1533. doi: 10.1056/NEJMc2112411. Epub 2021 Aug 27.

SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis.

Heart Fail Rev. 2022 May;27(3):951-960. doi: 10.1007/s10741-021-10083-z. Epub 2021 Feb 23.

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.

JAMA Cardiol. 2021 Feb 1;6(2):148-158. doi: 10.1001/jamacardio.2020.4511.

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.

Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30.

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.

Redefining Heart Failure With a Reduced Ejection Fraction.

JAMA. 2019 Nov 12;322(18):1761-1762. doi: 10.1001/jama.2019.15600.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献